SNSE holder plans Rule 144 sale of 1,169 shares

Sensei Biotherapeutics security holder plans a small stock sale under Rule 144.

Rhea-AI Filing Summary

Sensei Biotherapeutics security holder plans a small stock sale under Rule 144. The notice covers the proposed sale of 1,169 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 11,485.83.

The shares were acquired through restricted stock vesting from the issuer on several dates between 03/09/2023 and 03/09/2025 as compensation. The person filing represents that they are not aware of any material adverse, nonpublic information about the company’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SNSE Form 144 filing disclose?

The Form 144 for SNSE discloses a planned sale of restricted shares under Rule 144. It details the security class, number of shares, market value, acquisition method, and key representations by the selling holder regarding material nonpublic information.

How many SNSE shares are planned to be sold under this Form 144?

The notice covers a planned sale of 1,169 shares of SNSE common stock. These shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with the filing listing the estimated aggregate market value at 11,485.83 at the time of the notice.

How were the SNSE shares in this Form 144 acquired?

The SNSE shares were acquired through restricted stock vesting from the issuer as compensation. Vesting transactions occurred on 03/09/2023, 03/09/2024, 07/10/2024, and 03/09/2025, with specific share amounts listed for each date as equity-based compensation.

What does the seller represent about nonpublic information in the SNSE Form 144?

The seller represents that they do not know any material adverse information about SNSE’s current or prospective operations that has not been publicly disclosed. This representation is part of the standard certification language included in Rule 144 notices.

On which exchange will the SNSE shares in this Form 144 be sold?

The Form 144 specifies that the 1,169 SNSE common shares are intended to be sold on NASDAQ. The filing also identifies Fidelity Brokerage Services LLC as the broker handling the planned transaction for the selling security holder.

What is the aggregate market value of the SNSE shares in this planned Rule 144 sale?

The filing lists an aggregate market value of 11,485.83 for the 1,169 SNSE common shares. This figure reflects the market value at the time the notice was prepared for the proposed sale through the designated broker on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 05:33 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001238325
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Sensei Biotherapeutics, Inc.
SEC File Number	001-39980
Address of Issuer	1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MARYLAND 20850
Phone	(240) 243-8000
Name of Person for Whose Account the Securities are To Be Sold	RINGO WILLIAM R
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1169	11485.83	1261290	01/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/09/2023	Restricted Stock Vesting	Issuer			648	03/09/2023	Compensation
Common	03/09/2024	Restricted Stock Vesting	Issuer			149	03/09/2024	Compensation
Common	07/10/2024	Restricted Stock Vesting	Issuer			223	07/10/2024	Compensation
Common	03/09/2025	Restricted Stock Vesting	Issuer			149	03/09/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for William Ringo
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)